SEC Form 4 · accession 0001104659-16-101423

EPIRUS Biopharmaceuticals, Inc. · EPRS

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).

Reporting owner

Officer — Chief Technical Officer

Period of report

Feb 27, 2016

Accepted (ET)

Mar 1, 2016 · 4:09 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001135906

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock^F1	Feb 27, 2016	M	1,044	—	A	31,432	D
Common Stock^F2	Feb 27, 2016	M	2,608	—	A	34,040	D
Common Stock^F4	Feb 27, 2016	F	1,379	$2.80	D	32,661	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Restricted Stock Units^F1	—	Feb 27, 2016	M	1,044	D	—	—	Common Stock	1,044	0	D
Restricted Stock Units^F2	—	Feb 27, 2016	M	2,608	D	—	—	Common Stock	2,608	7,824	D

F1Each Restricted Stock Unit ("RSU") represented a contingent right to receive a share of the Issuer's common stock, vested in full on February 27, 2016, and had no expiration date.
F2Each RSU represents a contingent right to receive a share of the Issuer's common stock, vests in four (4) substantially equal annual installments beginning on February 27, 2016 provided the Reporting Person remains continuously employed by the Issuer through each vesting date, and has no expiration date.
F3Represents shares of the Issuer's common stock withheld by the Issuer to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portions of the RSUs as reflected in this Form 4.
F4Represents the closing price of shares of the Issuer's common stock on the business day prior to the vesting date for such RSUs.